{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:11Z","timestamp":1793398211282,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2025 Lanzhou Municipal Science and Technology Development Guiding Program","award":["2025-5-150"],"award-info":[{"award-number":["2025-5-150"]}]},{"name":"the 12th Batch of Provincial Science and Technology Plan (Joint Research Fund) Project of Gansu Province, China","award":["Grant No. 23JRRA1528"],"award-info":[{"award-number":["Grant No. 23JRRA1528"]}]},{"name":"the Open Project of the Key Laboratory of Dunhuang Medicine and Transformation, Ministry of Education, China","award":["Grant No. DHYX24-17"],"award-info":[{"award-number":["Grant No. DHYX24-17"]}]},{"name":"Key R&D Program of Gansu Province, China","award":["Grant No. 25YFFA044"],"award-info":[{"award-number":["Grant No. 25YFFA044"]}]},{"name":"the Gansu Provincial Higher Education Institutions Young Doctoral Support Project, China","award":["Grant No. 2025QB-064"],"award-info":[{"award-number":["Grant No. 2025QB-064"]}]},{"name":"the Innovation Base and Talent Plan Fund Project of Gansu Province, China","award":["Grant No. 21JR11RA191"],"award-info":[{"award-number":["Grant No. 21JR11RA191"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-48947-9","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:37:00Z","timestamp":1776346620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics and immune dynamics of peripheral blood immune cells and cytokines in individuals with chronic hepatitis B virus infection"],"prefix":"10.1038","volume":"16","author":[{"given":"Lixin","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuanli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"3","key":"48947_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","volume":"72","author":"M Cornberg","year":"2020","unstructured":"Cornberg, M., Lok, A. S., Terrault, N. A., Zoulim, F., Faculty E-AHTEC. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(\u2021). J. Hepatol. 72(3), 539\u2013557. https:\/\/doi.org\/10.1016\/j.jhep.2019.11.003 (2020).","journal-title":"J. Hepatol."},{"issue":"3","key":"48947_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","volume":"97","author":"J Liu","year":"2019","unstructured":"Liu, J., Liang, W., Jing, W. & Liu, M. Countdown to 2030: Eliminating hepatitis B disease, China. Bull. World Health Organ. 97(3), 230\u2013238. https:\/\/doi.org\/10.2471\/BLT.18.219469 (2019).","journal-title":"Bull. World Health Organ."},{"issue":"12","key":"48947_CR3","first-page":"881","volume":"13","author":"Chinese Society of Hepatology CMA and Chinese Society of Infectious Diseases CMA","year":"2005","unstructured":"Chinese Society of Hepatology CMA and Chinese Society of Infectious Diseases CMA. The guidelines of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 13(12), 881\u2013891 (2005).","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"2","key":"48947_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver. Electronic address eee and European Association for the Study of the L","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee and European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol. 67(2), 370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021 (2017).","journal-title":"J. Hepatol."},{"key":"48947_CR5","first-page":"276","volume":"22","author":"G Yeyinong","year":"2009","unstructured":"Yeyinong, G. [Three attacks in the development of HBV-related liver failure.]. Infect Dis Info. Chinese 22, 276 (2009).","journal-title":"Infect Dis Info. Chinese"},{"issue":"4","key":"48947_CR6","first-page":"241","volume":"4","author":"Z Dong","year":"2007","unstructured":"Dong, Z., Wei, H., Sun, R. & Tian, Z. The roles of innate immune cells in liver injury and regeneration. Cell. Mol. Immunol. 4 (4), 241\u2013252 (2007).","journal-title":"Cell. Mol. Immunol."},{"issue":"Suppl 1","key":"48947_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/liv.12749","volume":"35","author":"C Ferrari","year":"2015","unstructured":"Ferrari, C. HBV and the immune response. Liver Int. 35(Suppl 1), 121\u2013128. https:\/\/doi.org\/10.1111\/liv.12749 (2015).","journal-title":"Liver Int."},{"issue":"7","key":"48947_CR8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/gut.2008.163600","volume":"58","author":"P Fisicaro","year":"2009","unstructured":"Fisicaro, P. et al. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58(7), 974\u2013982. https:\/\/doi.org\/10.1136\/gut.2008.163600 (2009).","journal-title":"Gut"},{"issue":"17","key":"48947_CR9","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1073\/pnas.0401771101","volume":"101","author":"S Wieland","year":"2004","unstructured":"Wieland, S., Thimme, R., Purcell, R. H. & Chisari, F. V. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl. Acad. Sci. U. S. A. 101(17), 6669\u20136674. https:\/\/doi.org\/10.1073\/pnas.0401771101 (2004).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"48947_CR10","doi-asserted-by":"publisher","first-page":"721975","DOI":"10.3389\/fimmu.2021.721975","volume":"12","author":"I Baudi","year":"2021","unstructured":"Baudi, I., Kawashima, K. & Isogawa, M. HBV-Specific CD8\u2009+\u2009T-Cell Tolerance in the Liver. Front. Immunol. 12, 721975. https:\/\/doi.org\/10.3389\/fimmu.2021.721975 (2021).","journal-title":"Front. Immunol."},{"issue":"27","key":"48947_CR11","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.3748\/wjg.v25.i27.3527","volume":"25","author":"TY Li","year":"2019","unstructured":"Li, T. Y., Yang, Y., Zhou, G. & Tu, Z. K. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World J. Gastroenterol. 25(27), 3527\u20133537. https:\/\/doi.org\/10.3748\/wjg.v25.i27.3527 (2019).","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"48947_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault, N. A. et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63(1), 261\u2013283. https:\/\/doi.org\/10.1002\/hep.28156 (2016).","journal-title":"Hepatology"},{"issue":"2","key":"48947_CR13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver. Electronic address eee and European Association for the Study of the L","year":"2018","unstructured":"European Association for the Study of the Liver. Electronic address eee and European Association for the Study of the L. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 69(2), 406\u2013460. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.024 (2018).","journal-title":"J. Hepatol."},{"key":"48947_CR14","doi-asserted-by":"publisher","first-page":"156442","DOI":"10.1016\/j.cyto.2023.156442","volume":"173","author":"L Xiao","year":"2023","unstructured":"Xiao, L. et al. Cytokine profiles and virological markers highlight distinctive immune statuses, and effectivenesses and limitations of NAs across different courses of chronic HBV infection. Cytokine 173, 156442. https:\/\/doi.org\/10.1016\/j.cyto.2023.156442 (2023).","journal-title":"Cytokine"},{"key":"48947_CR15","doi-asserted-by":"publisher","first-page":"1025654","DOI":"10.3389\/fimmu.2022.1025654","volume":"13","author":"X Yuan","year":"2022","unstructured":"Yuan, X. et al. Describing immune factors associated with Hepatitis B surface antigen loss: A nested case-control study of a Chinese sample from Wuwei City. Front. Immunol. 13, 1025654. https:\/\/doi.org\/10.3389\/fimmu.2022.1025654 (2022).","journal-title":"Front. Immunol."},{"key":"48947_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cyto.2018.02.012","volume":"109","author":"N Karin","year":"2018","unstructured":"Karin, N. & Razon, H. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine 109, 24\u201328. https:\/\/doi.org\/10.1016\/j.cyto.2018.02.012 (2018).","journal-title":"Cytokine"},{"issue":"5","key":"48947_CR17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","volume":"317","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 in T cell function. Exp. Cell Res. 317(5), 620\u2013631. https:\/\/doi.org\/10.1016\/j.yexcr.2010.12.017 (2011).","journal-title":"Exp. Cell Res."},{"issue":"4","key":"48947_CR18","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/hep.30317","volume":"69","author":"Y Chen","year":"2019","unstructured":"Chen, Y., Hao, X., Sun, R., Wei, H. & Tian, Z. Natural killer cell-derived interferon-gamma promotes hepatocellular carcinoma through the epithelial cell adhesion molecule-epithelial-to-mesenchymal transition axis in hepatitis B virus transgenic mice. Hepatology 69(4), 1735\u20131750. https:\/\/doi.org\/10.1002\/hep.30317 (2019).","journal-title":"Hepatology"},{"issue":"8","key":"48947_CR19","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1172\/JCI63539","volume":"122","author":"SH Hsu","year":"2012","unstructured":"Hsu, S. H. et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Invest. 122(8), 2871\u20132883. https:\/\/doi.org\/10.1172\/JCI63539 (2012).","journal-title":"J. Clin. Invest."},{"issue":"1","key":"48947_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1055\/s-0038-1676806","volume":"39","author":"YM Yang","year":"2019","unstructured":"Yang, Y. M., Kim, S. Y. & Seki, E. Inflammation and liver cancer: Molecular mechanisms and therapeutic targets. Semin. Liver Dis. 39(1), 26\u201342. https:\/\/doi.org\/10.1055\/s-0038-1676806 (2019).","journal-title":"Semin. Liver Dis."},{"issue":"13","key":"48947_CR21","doi-asserted-by":"publisher","first-page":"17021","DOI":"10.18632\/oncotarget.7740","volume":"7","author":"C Li","year":"2016","unstructured":"Li, C. et al. Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget 7(13), 17021\u201317034. https:\/\/doi.org\/10.18632\/oncotarget.7740 (2016).","journal-title":"Oncotarget"},{"issue":"7","key":"48947_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/gutjnl-2013-306302","volume":"64","author":"YT Shih","year":"2015","unstructured":"Shih, Y. T. et al. Endothelial progenitors promote hepatocarcinoma intrahepatic metastasis through monocyte chemotactic protein-1 induction of microRNA-21. Gut 64(7), 1132\u20131147. https:\/\/doi.org\/10.1136\/gutjnl-2013-306302 (2015).","journal-title":"Gut"},{"key":"48947_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2003","author":"Z Farhat","year":"2022","unstructured":"Farhat, Z. et al. A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer. Hepatol. Commun. https:\/\/doi.org\/10.1002\/hep4.2003 (2022).","journal-title":"Hepatol. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48947-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:29:32Z","timestamp":1780957772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-48947-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["48947"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-48947-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The experimental protocol was established according to the ethical guidelines of the Helsinki. Ethical approval for this study was granted by the Medical Ethics Committee of Lanzhou Petrochemical General Hospital (Approval Number: [LZSH-IEC-2024-098-1]). Written informed consent was obtained from each participant before enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors thank the participants who agreed to participate and made this study possible.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"17712"}}